ATC Group: R03DC03 Montelukast

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of R03DC03 in the ATC hierarchy

Level
Code
Title
1
Respiratory system
2
Drugs for obstructive airway diseases
3
Other systemic drugs for obstructive airway diseases
4
Leukotriene receptor antagonists
5
R03DC03
Montelukast

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route
Amount
ORAL - Oral
10 mg

Active ingredients in R03DC03

Active Ingredient
Description

Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. ฮคhe CysLT type-1 (CysLT1) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells (including eosinophils and certain myeloid stem cells). CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis.

Related product monographs

Title
Information Source
Document Type
 
Medicines Authority (MT)
Summary of Product Characteristics (SPC)
Medicines & Healthcare Products Regulatory Agency (GB)
Summary of Product Characteristics (SPC)
FDA, National Drug Code (US)
Structured Product Labeling (SPL/PLR)

Medicines in this ATC group

United States (US)

Australia (AU)

Austria (AT)

Canada (CA)

Finland (FI)

France (FR)

Ireland (IE)

Japan (JP)

Lithuania (LT)

Mexico (MX)

Netherlands (NL)

Nigeria (NG)

Romania (RO)

United Kingdom (UK)

While we strive to include the brand names of medicines across all countries, our index remains incomplete. Therefore, it is possible that this medicine may also be marketed under different names in other countries.